Sherwood Pharmaceuticals is a fresh start-up dedicated to rapidly bringing potential therapies to cri du chat syndrome patients, also known as 5p monosomy. In Europe and the United States there are an estimated 10K patients and more across the globe, but there are no dedicated therapies. Working in close partnership with the Cri du Chat Research Foundation, we have identified an immediate drug repurpose opportunity. Our proposed treatment could improve patients’ neurological functioning and potentially other aspects of their condition. We are currently seeking seed funding to initiate the trial by the end of 2025 to facilitate our straight shot to the clinic.